TY - JOUR
T1 - Corrigendum
T2 - Fucosylated Antigens in Cancer: An Alliance Toward Tumor Progression, Metastasis, and Resistance to Chemotherapy
AU - Blanas, Athanasios
AU - Sahasrabudhe, Neha M.
AU - Rodríguez, Ernesto
AU - van Kooyk, Yvette
AU - van Vliet, Sandra J.
PY - 2018
Y1 - 2018
N2 - We recently published our review with the title: "Fucosylated Antigens in Cancer: An Alliance Toward Tumor Progression, Metastasis, and Resistance to Chemotherapy" in Frontiers in Oncology. However, we noticed that there is a mistake in the abstract of the article. Specifically, the abstract mentions "endothelial to mesenchymal transition" instead of "epithelial to mesenchymal transition." We are submitting this Corrigendum in order to clarify the error and apologize for any confusion by the readers. The correct sentence should read: "Here, we review the relevance of tumor-overexpressed FUTs and their respective synthesized Lewis determinants in critical aspects associated with cancer progression, such as increased cell survival and proliferation, tissue invasion and metastasis, epithelial to mesenchymal transition, endothelial and immune cell interaction, angiogenesis, multidrug resistance, and cancer stemness".
AB - We recently published our review with the title: "Fucosylated Antigens in Cancer: An Alliance Toward Tumor Progression, Metastasis, and Resistance to Chemotherapy" in Frontiers in Oncology. However, we noticed that there is a mistake in the abstract of the article. Specifically, the abstract mentions "endothelial to mesenchymal transition" instead of "epithelial to mesenchymal transition." We are submitting this Corrigendum in order to clarify the error and apologize for any confusion by the readers. The correct sentence should read: "Here, we review the relevance of tumor-overexpressed FUTs and their respective synthesized Lewis determinants in critical aspects associated with cancer progression, such as increased cell survival and proliferation, tissue invasion and metastasis, epithelial to mesenchymal transition, endothelial and immune cell interaction, angiogenesis, multidrug resistance, and cancer stemness".
UR - https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85046668210&origin=inward
UR - https://www.ncbi.nlm.nih.gov/pubmed/29795807
U2 - https://doi.org/10.3389/fonc.2018.00150
DO - https://doi.org/10.3389/fonc.2018.00150
M3 - Erratum/Corrigendum
C2 - 29795807
SN - 2234-943X
VL - 8
JO - Frontiers in Oncology
JF - Frontiers in Oncology
IS - MAY
M1 - 150
ER -